Vision Failure Means End Of The Road For Oxurion
Disappointing data from a trial of the last remaining drug in its pipeline means that the Belgium group formerly known as ThromboGenics is closing its doors after more than 30 years.
Disappointing data from a trial of the last remaining drug in its pipeline means that the Belgium group formerly known as ThromboGenics is closing its doors after more than 30 years.